A New Era for Obesity Pills
Novo Nordisk has announced a major partnership with U.S.-based biotech Septerna, striking a deal worth up to $2.2 billion to develop next-generation oral treatments for obesity, type 2 diabetes, and other cardiometabolic diseases[1][2][6].
This move will reshape the competitive landscape of the rapidly growing diabesity drug market.
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
